Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorJody W.ZylkeMD, Contributing EditorIndividualAuthor
In Reply: The letter received by Dr Sperber
was sent to health care providers following the numerous requests for information
Merck & Co received after the publication and ensuing media reports of
the article by Mukherjee et al.1 The letter
we sent included selected safety information and the full text copy of the
prescribing information for Vioxx (rofecoxib). In addition, Merck did send
a letter to the editor (of JAMA) to express our views and recently published
an article2 that provided a pooled analysis
of the cardiovascular safety data for rofecoxib.
Sherwood LM. Cardiovascular Events and COX-2 Inhibitors—Reply. JAMA. 2001;286(22):2808–2813. doi:10.1001/jama.286.22.2808
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: